-
Views
-
Cite
Cite
In this issue, Nephrology Dialysis Transplantation, Volume 24, Issue 3, March 2009, Pages i–ii, https://doi.org/10.1093/ndt/gfp046
Close - Share Icon Share
Extract
An editorial comment critically evaluates CKD classification and suggests that the classification of CKD should be improved, particularly for stage 3 where the clinician's input will likely be required.
See editorial comment by Poggio and Rule, pages 698–700
A lucid editorial comment on recently published meta-analyses that question the use of some β-blockers, mostly atenolol, in hypertension. The authors, experts in the field, recommend that given the high prevalence of CVD in CKD, and the observed mortality benefits seen with at least some vasodilating β-blockers, there is a clear need for their use in CKD patients.
See editorial comment by Kalaitzidis and Bakris, pages 701–702
A survival benefit has been described in haemodialysis patients treated with intravenous vitamin D. An editorial comment and an analysis by DOPPS caution that many of the studies claiming this advantage used retrospective studies including historical controls. The DOPPS analysis, however did not observe differences in mortality in instrumental variable models that account for unmeasured confounders.
Comments